Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Krabbe disease, also called globoid cell leukodystrophy or galactosylceramidase deficiency, is described in the packet as a lysosomal disorder that affects the white matter of the central and peripheral nervous systems, with infantile, late-infantile/juvenile and adult forms. GeneReviews describes two major phenotypes that form a continuum: infantile-onset disease (onset before 12 months), with progressive neurologic deterioration in infancy, and later-onset disease (onset after 12 months, as late as the seventh decade), with slower progression. Historically, 85%-90% of symptomatic individuals diagnosed by enzyme activity alone had infantile-onset disease and 10%-15% had later-onset disease; GeneReviews adds that most infants identified through New York State newborn screening with low GALC activity and two presumptive pathogenic GALC variants did not have infantile-onset signs. The packet prevalence field gives the category uncommon with an estimate of 1-9 in 100,000. GeneReviews states approximately one in 250,000 births in the United States and approximately one in 100,000 births in Europe, varying widely between countries, with a very high incidence in a Druze community in northern Israel (carrier rate estimated at one in six).
The packet lists 28 phenotype terms, five of which carry frequency data. Reduced tissue galactocerebrosidase activity and progressive spasticity are listed as obligate (100%, always present). Axial hypotonia and developmental regression are listed as frequent (30-79%), and CNS demyelination as occasional (5-29%). GeneReviews describes infantile-onset disease as typically having four stages. In Stage I, an infant who is apparently normal for the first few months begins to cry frequently without apparent cause, and feeding difficulties and reflux may cause progressive weight loss. Stage II involves rapid severe neurologic deterioration with decorticate posturing and absent tendon reflexes. Stage III involves poor control of temperature and heart rate, blindness, deafness and seizures. Stage IV involves very low muscle tone and absence of voluntary movement. GeneReviews states that symptoms and signs are confined to the nervous system and that no visceromegaly is present. For later-onset disease, GeneReviews describes children with onset between 12 months and three years who can be clinically normal until gait changes, hemiplegia or diplegia, visual impairment, febrile seizures or tremors appear. Progression is described as variable.
The packet lists GALC as the known gene, located on chromosome 14, with a ClinGen validity classification of DEFINITIVE, and lists autosomal recessive as the inheritance pattern. According to GeneReviews, infantile-onset disease has been associated with homozygosity for the common GALC 30-kb deletion, or compound heterozygosity for that deletion and a severe GALC pathogenic variant, or for two severe pathogenic variants. For later-onset disease, GeneReviews lists several observed genotypes, including p.Gly286Asp with another severe allele, and describes a founder variant common in Catania, Italy; it states that clinical course cannot be predicted in a given individual. GeneReviews states that parents of an affected individual are obligate carriers, that carriers are asymptomatic, and that at conception each sibling of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier and a 25% chance of being unaffected and not a carrier.
GeneReviews describes two scenarios in which Krabbe disease is suspected: a symptomatic individual, and an asymptomatic newborn with a positive newborn screening result. Findings listed for infantile-onset disease include excessive crying to extreme irritability, feeding difficulties, lower-extremity spasticity with axial hypotonia, loss of acquired milestones, staring episodes and peripheral neuropathy; findings listed for later-onset disease include slow or lost motor milestones, slurred speech, spasticity, vision loss, esotropia, seizures and peripheral neuropathy. Supportive findings include increased cerebrospinal fluid protein, MRI consistent with demyelination, and abnormal electrophysiologic studies. GeneReviews states that in a symptomatic individual the diagnosis is established by detection of deficient GALC enzyme activity in leukocytes (0%-5% of normal activity in all symptomatic individuals), with abnormal results followed by molecular genetic testing of GALC. Elevated psychosine in dried blood spots is described as confirming the diagnosis in infantile-onset disease; whether it is consistently elevated in later-onset disease is not yet known. GeneReviews reports that seven states (Illinois, Kentucky, Missouri, New York, Ohio, Pennsylvania and Tennessee) perform newborn screening for GALC deficiency using dried blood spots, with cut-off values varying by state. GeneReviews describes differentiation from other degenerative diseases as often difficult; its differential diagnosis includes metachromatic leukodystrophy, hexosaminidase A deficiency (including Tay-Sachs disease), Canavan disease and saposin A deficiency.
The packet lists orphan drug entries for Krabbe disease, including several adeno-associated virus vector gene therapy candidates, gemfibrozil, ibudilast and trans-cinnamic acid with status DESIGNATED, and two entries with status WITHDRAWN. No entry carries an active marketing status, so FDA-approved treatment is not certified in this packet; orphan designation is not marketing approval. GeneReviews describes management as supportive for a child younger than six months in Stage II or III of infantile-onset disease, focused on quality of life and limiting complications. For individuals who have not undergone hematopoietic stem cell transplantation (HSCT), GeneReviews tabulates manifestation-specific approaches: upright positioning, modified food textures, tube feeding and fundoplication for gastrointestinal concerns; baclofen, clonazepam and botulinum toxin injections for spasticity; standard anti-seizure medications and gabapentin for seizures and neuropathic pain; positioning devices and physical therapy for contractures; and chest physiotherapy for airway secretions. GeneReviews lists surveillance for hydrocephalus, scoliosis, hip subluxation, osteopenia, decreased vision, corneal ulceration and swallowing difficulties. GeneReviews reports that 11 asymptomatic newborns who underwent HSCT between ages 12 and 44 days had stable engraftment of donor cells providing a long-term source of GALC enzyme.
9 trials found
GeneReviews states that the average age of death in children with infantile-onset Krabbe disease is 24 months, that some die by age eight months from infections and respiratory failure, and that others live up to age nine years. For newborn HSCT, GeneReviews reports that among 11 asymptomatic newborns followed for four months to six years, most had normal cognitive ability and receptive language but eventually developed speech and motor difficulties, including spasticity. In a 15-year study of 18 individuals who underwent HSCT in the first seven weeks of life, long-term motor function reflected corticospinal tract involvement at birth, and peripheral nerve disease progressed, causing severe muscular atrophy and scoliosis. GeneReviews states that, compared with children not treated as babies, those treated early can live relatively normal lives with variable motor disabilities until the teen years, when the disease may progress.
The packet lists eight ClinicalTrials.gov records for Krabbe disease: NCT02171104 (Allo HCT for Metabolic Disorders and Severe Osteopetrosis; Phase 2; University of Minnesota; active, not recruiting); NCT02993796 (Krabbe Disease Global Patient Registry; State University of New York at Buffalo; recruiting); NCT07740512 (PLX-200 in Pediatric Patients, Master Protocol; Phase 2; Polaryx Therapeutics; not yet recruiting); NCT03655223 (Early Check: Expanded Screening in Newborns; RTI International; active, not recruiting); NCT00787865 (Diffusion Tensor Imaging in Infants With Krabbe Disease; University of Pittsburgh; active, not recruiting); NCT03333200 (Longitudinal Study of Neurodegenerative Disorders; University of Pittsburgh; recruiting); NCT05739643 (Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT; Phase 1; Forge Biologics; active, not recruiting); and NCT03047369 (The Myelin Disorders Biorepository Project; Children's Hospital of Philadelphia; recruiting). GeneReviews states that animal-model studies are investigating enzyme replacement, neural stem cell transplantation, substrate reduction and chemical chaperone therapy, and that combined HSCT and gene therapy increased life span in a GALC-deficient mouse model.
Data assembled from 10 of 12 sources · Last updated Nov 18, 2026, 8:42 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning Krabbe disease
Updated Sep 2, 2026
The Krabbe Disease Treatment Market reached approximately USD 262 25 million in 2025 and is expected to reach nearly USD 786 45 million by 2033 growing at a CAGR of 16 8 during the forecast period from 2026 to 2033 ... Regional Insights: -North America: 42.8% (Largest share, supported by advanced healthcare infrastructure, comprehensive newborn screening programs, specialized treatment centers, and strong clinical research activity). -Europe: 28.6% (Second-largest share, driven by well-established healthcare systems, rare disease policies, collaborative research networks, and access to specialized therapies). Press release - DataM Intelligence 4 Market Research LLP - Krabbe Disease Treatment Market to Reach USD 786.45 Million as U.S. Gene Therapy Clinical Trials Accelerate Through 2033 - published on openPR.com
Recent molecular dynamics simulations have analyzed four GALC variants linked to Krabbe disease, providing insights into their structural impacts. This research enhances understanding of the disease mechanisms and may inform future therapeutic strategies.
A recent study provides clinical and molecular insights into Krabbe disease among Iranian patients, contributing to the understanding of this rare genetic disorder. The case report highlights unique characteristics and expands the existing literature on Krabbe disease.
A rare case study highlights brachial plexopathy in juvenile-onset Krabbe disease, contributing to the understanding of this condition. This discovery may inform future research and clinical approaches to managing symptoms in affected patients.